The aims of this study were to establish the nutritional status of patients during hematopoietic SCT (HSCT) and to determine if body mass index (BMI) is a valid indicator of nutritional status in this population when compared with nitrogen balance (NB). In total, 50 patients were enrolled (mean age: 25.7 ± 9.0 years). Patients (14%) were underweight (BMIo18.5 kg/m 2 ), 58% in a normal BMI (between 18.5 and 24.9 kg/m 2 ) and 28% were overweight or obese (BMIX25 kg/m 2 ). NB dropped after transplantation and increased from days þ 5 to þ 20 after transplantation (P ¼ 0.006). There was a significant negative relationship between patients' BMI and time to engraftment (r ¼ À0.45, P ¼ 0.001). Engraftment of underweight patients was 3.0 days (P ¼ 0.002) and 4.0 days (Po0.001) later than in normal and overweight or obese patients, respectively. There was no significant correlation between NB before transplantation and time to engraftment (r ¼ À0.22, P ¼ 0.16). The results of this study demonstrate that patients undergoing HSCT may have suboptimal nutritional status and that pre-HSCT-BMI rather than NB may have a greater correlation in HSCT patients with the time of engraftment. Therefore, it may be useful to consider patient's BMI before transplantation for earlier engraftment time.
Introduction
Hematopoietic SCT (HSCT) including both BMT and peripheral blood SCT (PBSCT) is being used increasingly in an attempt to cure many hematological disorders, solid tumors and autoimmune diseases. One of the major challenges in the post transplant period is nutrition. 1 Impaired nutritional status before transplantation is a negative prognostic factor for outcome after HSCT. 2 In fact, the better nourished patients have a shorter time to engraftment. 3 Irrespective of nutritional status, however, nutritional support is frequently delivered routinely after HSCT to prevent malnutrition secondary to either gastrointestinal toxicity related to the conditioning regimen or to increased nutrient requirements. HSCT has a dramatic effect on the recipient, affecting protein, energy and micronutrient metabolism. [4] [5] [6] [7] Biochemical indices have been shown to not accurately reflect changes in nutritional status of HSCT recipients, 8 and anthropometric measurements may be influenced by fluid and electrolyte disturbances. [9] [10] [11] [12] Negative nitrogen balance (NB) is common in HSCT patients 13 as a consequence of both intestinal losses with diarrhea and catabolic effects on skeletal muscle. These effects are initially exerted by the underlying disease, then by conditioning regimens, and possible HSCT complications such as infections and GVHD. 4, 14 NB is a direct expression of the imbalance between protein breakdown and synthesis.
14 It is considered the most accurate way to perform nutritional assessment in HSCT patients. 15 In this study, we assessed nutritional status by using NB in patients undergoing HSCT before transplantation and at different time points thereafter. The use of body mass index (BMI) to determine nutritional status in pre-HSCT patients has been documented in previous studies and is used in many clinical centers. The secondary aim of our study was to determine if BMI is a valid indicator of nutritional status in this population when compared with NB. Table 1 . Patients were excluded if they had respiratory, hepatic, renal and cardiac dysfunction. All parameters were evaluated 5 days before transplantation (À5), and 5, 10 and 20 days after stem cells infusion ( þ 5, þ 10 and þ 20, respectively).
Patients and methods

Patients
Subjects were weighed to the nearest 0.05 kg using calibrated digital scales and height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. BMI was calculated as weight (kg) divided by height (m) squared. BMI values were classified into three groups: BMI o18.5 kg/m 2 as underweight, BMI between 18.5 and 24.9 kg/m 2 as normal, and BMIX25 kg/m 2 as overweight or obese.
Conditioning regimen
All patients received pretransplant conditioning regimen consisting of one of the following: BU/CY; CY/fludarabine; CY/anti-thymocyte globulin (ATG); CCNU (Lomustine)/VP16/CY or melphalan.
GVHD prophylaxis and treatment
Acute GVHD was diagnosed on the basis of clinical symptoms of skin, oral mucosa, gut and liver. Grading of GVHD was from 0 (absent) to IV according to published criteria. 16 Prophylaxis against GVHD was given to all patients and consisted of CsA and low-dose MTX. Methylprednisolone was given to patients with uncontrolled GVHD. If no response was obtained, ATG was added to the regimen.
Mucositis of the gastrointestinal tract
Almost all patients undergoing HSCT, develop oroesophageal mucositis and gastrointestinal toxicity within 7-10 days after chemotherapy. As a result patients have decreased oral intake, nausea, diarrhea and vomiting. Even though both the severity and the duration of gastrointestinal toxicity may differ among individuals, but the condition significantly affects food intake and absorption for up to 2-3 weeks after HSCT. 17 Dietary intakes, nitrogen balance and energy requirements Patients' food intake was observed and recorded by a nutritionist for 3 consecutive days and daily intake of energy and protein was calculated using Food Processor software. Energy and protein amounts of parenteral nutrition (PN) were added to obtained values. Patients' pre-HSCT energy requirements were calculated as 1.4Xbasal metabolic rate (BMR) and 1.7 Â BMR during 20 days after BMT. 18 BMRs were estimated according to the HarrisBenedict equation. 19 At 24 h urine collection was performed and urinary urea nitrogen (UUN) was measured enzymatically. NB was calculated using the following equation: 20 NB ¼ grams of nitrogen intakeÀ(grams of nitrogen excretion (UUN) þ 3)
Nitrogen intake was calculated by dividing the amount of protein intake to 6.25.
Engraftment
Myeloid engraftment following HSCT has conventionally been defined as the first of 3 consecutive days the patient presents an ANC of 0.5 Â 10 9 per liter or more.
21-24
Statistical analysis Statistical analyses were performed using the SPSS package for statistics version 11.5. Data were presented as mean±s.d. values; and Po0.05 was considered significant. Correlation analysis was performed to determine correlation of pre-HSCT NB values and BMI categories with the time to engraftment.
Results
Patients' body weight, energy intake, the ratio of energy intake/energy requirements and NB during the study are shown in Table 2 . Distribution of patients in different categories of BMI and NB, and the time of engraftment in each subgroup are shown in Table 3 .
The trends in body weight, energy intake and NB changes are presented in Figures 1-3 . Body weight and energy intake declined until 10 days after transplantation and thereafter increased from days þ 10 to þ 20 after transplantation. The NB dropped after transplantation and increased from days þ 5 to þ 20 after transplantation. The changes in body weight and NB during the 1-year study period were significant (Po0.001 and P ¼ 0.006, respectively). Correlation analysis showed that there was a significant and negative relationship between patients' BMI and time to engraftment (r ¼ À0.45, P ¼ 0.001; Figure 4 ). Engraftment of underweight patients was 3.0 
T(À5) ¼ 5 days before SCT; T(+5) ¼ 5 days after SCT; T(+10) ¼ 10 days after SCT; T(+20) ¼ 20 days after SCT.
Nutrition assessment in hematopoietic SCT M Hadjibabaie et al days (P ¼ 0.002) and 4.0 days (Po0.001) later than in normal and overweight or obese patients, respectively. There was no significant correlation between NB before transplantation (day À5) and the time of engraftment (r ¼ À0.22, P ¼ 0.16; Figure 5 ). In addition, no significant correlation was observed between NB after transplantation (days þ 5, þ 10 and þ 20) and engraftment either. Sixteen patients (32%) had a bacteremia with one positive blood culture. There were no significant differences in the length of hospitalization and time to engraftment between allogeneic and autologous transplanted patients.
Nutrition
Most patients were able to tolerate oral intake during their hospital stay, but PN was given as a supplement to almost Nutrition assessment in hematopoietic SCT M Hadjibabaie et al all patients every other day. Five patients were unable to tolerate oral intake for an average of 3 days (2-7 days) and they received total parenteral nutrition.
Post transplant complications GVHD grade 0 developed in 44%, grade I in 8.8%, grade II in 26.5% and grade III in 20.6% of patients after allo-HSCT. Mucositis stage 0 developed in 32.4 and 12.5%, stage I in 41.2 and 65.5%, stage II in 11.8 and 25% and stage III in 14.7 and 0% of patients after allogeneic and autologous transplantation, respectively. We did not find any correlation between BMI and the incidence and severity of the mucositis or GVHD. In addition, there was no correlation between NB (days before and after HSCT) and mucositis but the NB at days þ 10 and þ 20 was significantly higher in grade I compared with grades II and III GVHD (Po0.05).
Discussion
HSCT is a highly stressful condition requiring a high level of energy. This stressful condition results from a hypermetabolic state in which increased catabolism and anabolism are intertwined as a consequence of cytoreductive therapy, occurrence of complications such as infections, multiple organ failure and tissue repairing. 25 In addition, increased energy requirement, fluid restrictions and hepatotoxicity of PN make it difficult to provide adequate nutrition consistently. 26 To ensure the nutritional status of patients during HSCT is optimal, it is crucial that nutritional status be monitored accurately and that individual energy requirements provided. Impaired nutritional status before HSCT has been known to be a negative prognostic factor, whereas well-nourished patients having a shorter engraftment time. 27 The aims of this study were to determine the nutritional status of patients undergoing HSCT and to examine whether BMI and NB are good predictive methods of assessing the days to engraftment in this population. The nutritional status of patients during HSCT is not well documented in the literature and different methods have been used to determine nutritional status. One study showed that 100 patients undergoing HSCT were at or above ideal body weight and none had a history of significant weight reduction (410% in previous 6 months). 28 However, in another study, 73% of patients were well nourished, 23% were moderately malnourished or at risk of malnutrition and 4% were severely malnourished. 29 Our study found that 14% of patients undergoing HSCT were underweight (BMI below 18.5 kg/m 2 ) and 40% were in a negative state of NB. Considering our findings of suboptimal nutritional status in our HSCT patients and the results of previous studies, which have demonstrated that weight and NB decrease further after HSCT in adult subjects, it is recommended that patients undergoing HSCT be provided with nutritional support and that nutritional status closely monitored to ensure early identification of malnutrition.
Although the occurrence of acute GVHD could be regarded as a positive event because of GVL effect, this is a major complication occurring from 7-10 days to p3 months after allo-BMT in 30-60% of patients. 30 One study showed that poor oral intake early after HSCT may be associated with an increased risk of developing severe acute GVHD. 31 Mucositis after chemotherapy can also affect oral intake and food absorption. In our study, we did not find any correlation between BMI and incidence and severity of mucositis or GVHD. There was no correlation between NB and mucositis but the NB at days þ 10 and þ 20 was significantly higher in grade I in comparison with grades II and III. This can be explained by toxicity of gastrointestinal tract that can cause decreased nutrient absorption and loss of nutrients from the gut, especially amino acids due to altered transmembrane transport of nutrients.
The results of this study demonstrate that engraftment occurs earlier in patients with higher levels of BMI. This is also true for patients with higher levels of NB, but we found that BMI was a better predictive of engraftment time than NB (r ¼ À0.45, P ¼ 0.001 versus r ¼ À0.22, P ¼ 0.16).
A limitation of our study is that we did not assess body composition to distinguish the effective component of body mass.
In our patients, pre-HSCT BMI was a strong predictor of engraftment time. This is a simple measurement, so it is recommended for clinicians to consider the weight of patients who will undergo HSCT in the future and well nourishment of underweight patients' pre-HSCT period. Further studies on body composition of patients' pre-HSCT are required to identify the effective component of body mass. 
